TG1101-RMS404 - A Post-Authorization Study to Characterize the Safety of BRIUMVI (ublituximab) Use in Pregnant Patients with Multiple Sclerosis Using Data from a US Administrative Healthcare Claims Database First published 05/06/2025 Last updated 07/10/2025 EU PAS number:EUPAS1000000612 Study Ongoing